Pharming Group

Pharming Group EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Pharming Group (PHARM.AS) as of Nov 18, 2026 is 52.90. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -301.37 — a change of -117.55% (higher).

EV/EBIT

52.90

YoY

-117.55%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Pharming Group is 2025 52.90 . EV/EBIT (Enterprise Value to EBIT) of Pharming Group was 2024 -301.37 . It decreases by -117.55% higher compared to the previous year.

The Pharming Group EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
16.19 USD
Jan 1, 2020
13.46 USD
Jan 1, 2021
39.68 USD
Jan 1, 2022
60.58 USD
Jan 1, 2023
-54.19 USD
Jan 1, 2024
-301.37 USD
Jan 1, 2025
52.90 USD
Jan 1, 2026 (e)
22.51 USD
The Pharming Group EV/EBIT history
YEAREV/EBITYoY
est22.51-57.44%
52.90-117.55%
-301.37+456.14%
-54.19-189.45%
60.58+52.68%
39.68+194.86%
13.46-16.88%
16.19-36.30%
25.42-39.51%
42.02-146.17%
-91.01+15.61%
-78.72-124.93%
315.72—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pharming Group Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Pharming Group's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Pharming Group's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Pharming Group's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Pharming Group grows earnings faster than its peers.

Pharming Group Stock analysis

What does Pharming Group do? Pharming Group NV was founded in 1988 and is headquartered in the Netherlands. The company specializes in the development and marketing of medical products for the treatment of rare diseases. Its business model is based on the discovery and development of recombinant proteins. These proteins are produced using genetic engineering techniques and serve as the foundation for the development of therapeutic products in various areas. The main focus of Pharming Group NV is the manufacturing and marketing of biopharmaceuticals. The company has a wide range of products used in the treatment of rare diseases, including C1-esterase inhibitor preparations used for acute attacks in hereditary angioedema. Another important product of Pharming Group NV is recombinant human lysozyme. It is used in the treatment of cystic fibrosis and has shown promising results as a therapeutic approach. Pharming Group NV also collaborates closely with various research and development organizations to develop new products and expand knowledge in the medical industry. The company has experienced impressive growth in recent years. In 2019, Pharming Group NV achieved a revenue of 149 million euros. A significant portion of this revenue was generated through the sale of C1-esterase inhibitor preparations. Pharming Group NV has also made a name for itself in the international market. The company has branches in the USA and Europe and works closely with international regulatory authorities to ensure smooth approval and marketing of its products. Overall, Pharming Group NV has a promising future as it continues to invest in research, development, and expansion of its product portfolio. By focusing on the development of products for the treatment of rare diseases, Pharming Group NV positions itself as a leading company in the medical industry and contributes to improving the lives of people worldwide. Pharming Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pharming Group stock

EV/EBIT (Enterprise Value to EBIT) of Pharming Group is 52.90 in 2025.

EV/EBIT (Enterprise Value to EBIT) of Pharming Group changed from -301.37 to 52.90, representing a -117.55% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Pharming Group since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Pharming Group with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Pharming Group

All Key Metrics — Pharming Group